Technology

Institute for Systems Biology awarded $13M to study administering cancer drugs in succession – GeekWire


The National Cancer Institute has awarded Seattle’s Institute for Systems Biology $13 million to lead a collaborative cancer center studying two key types of cancer therapies: targeted therapies and immunotherapies. Using mouse models of cancer and human tissue, researchers will administer the two types of therapies in succession and compare the response to administration individually or in simultaneous combination.

Scientists will build computational models of the tumor response and design clinical trial concepts. “There is emerging evidence that starting these therapies in specific sequences before their combination might extract the most benefits for the patients,” said ISB president Dr. Jim Heath in a statement. Heath will lead the new program.





Source link

Related posts

BlackRock leads $100M round for Cap Hill Brands; e-commerce vets acquire 35 brands, add key execs – GeekWire

Laura Peterson

Seattle jumps to No. 9 in global startup ecosystem rankings – GeekWire

Laura Peterson

This startup raised $4M for software that analyzes workplace communication – GeekWire

Laura Peterson